Proactive Investors - Run By Investors For Investors

Radius soars as Amgen sees mixed results for osteoporosis drug

Amgen's new osteoporosis treatment may not be as effective as a rival drug being developed by Radius.
Radius soars as Amgen sees mixed results for osteoporosis drug
Romo may generate sales of $1bn but faces competition from Radius’s experimental drug.

Shares in Radius Health (NASDAQ:RDUS) jumped by 27% as a rival osteoporosis treatment, romo, developed by Amgen (NASDAQ:AMGN) produced mixed results in a phase III trial.

The Amgen drug Romosozumab, or romo, achieved its primary endpoint of a significantly reduced risk of spinal fracture, but did not reduce breaks outside the spine area over longer period, its secondary endpoint.

Even so, Amgen and its Belgian partner UCB intend to file for regulatory approval later this year.

Analysts suggest Romo may generate sales of $1bn but faces competition from Radius’s experimental drug abaloparatide and also from an Eli Lily drug, Forteo, which comes off patent soon.

Abaloparatide reduced the risk of spinal fracture by 86% in its phase III trial compared to romo’s 73%, though it has to be injected daily compared to once a month with Amgen/UCB’s drug.

Amgen added that when combined over two years with Prolia, its current osteoporosis drug, the reduction rose to 75%.

Amgen said although Romo, designed to inhibit the protein sclerostin, reduced both spine and non-spine fractures in the first year, it did not repeat the performance in non-vertebral fractures in the second year.

Blocking sclerostin increases bone formation.

Shares in Amgen fell 2% to US$147.5 while Radius climbed US$7.24 to US$34.24.

View full RDUS profile View Profile

Related Articles

couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
Frosties Box
December 04 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use